The Rare Diseases Clinical Research Network (RDCRN) is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI).
Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation.
Established by Congress under the Rare Diseases Act in 2002,[1] the RDCRN has included more than 350 sites in the United States and more than 50 in 22 other countries.
To date, they have encompassed hundreds of research protocols and included more than 56,000 participants in studies ranging from immune system disorders and rare cancers to heart and lung disorders, brain development diseases, and more.
[2] The following is a timeline of the Rare Diseases Clinical Research Network: The RDCRN Contact Registry[9][10] is a patient contact registry sponsored by the National Institutes of Health (NIH).